TrialInternational journal of clinical oncology2026

The fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in Chinese patients with HER2-positive early breast cancer: primary analysis of the phase III, randomized FDChina study.

Tao Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.